Clinical TrialsEnlivex has already reported positive interim three- and six-month efficacy data for the first 12 patients treated in this Phase 1 stage, with statistically significant improvements in all key efficacy endpoints and no safety issues.

Intellectual PropertyChinese patent claims allowed, covering Allocetra application in treatment of osteoarthritis, providing added intellectual property protection in China through at least 2040.

Market SentimentOsteoarthritis emerges as a key clinical Allocetra indication, raising price target to $7.

Bears Say

Regulatory ChallengesThe Phase 2 stage has a double-blind, randomized, placebo-controlled, multi-center design, which could potentially present hurdles in trial implementation.

Enlivex News

Enlivex to present 3-month data from Phase IIa osteoarthritis trial

Enlivex Therapeutics (ENLV) announced it will host a webinar on Monday, August 18, 2025 to present and discuss...

1d ago

ENLV

Enlivex reaffirms August 18 as target date for Phase II data announcement

Enlivex Therapeutics (ENLV) announced that all 134 patients in its Phase II stage of its randomized, controlled, blinded...

18d ago

ENLV

Enlivex to Present Key Results from Osteoarthritis Trial

An update from Enlivex ( ($ENLV) ) is now available. On August 14, 2025, Enlivex Therapeutics announced it...

1d ago

ENLV

Enlivex Therapeutics’ Promising Study on Allocetra for Knee Osteoarthritis

Enlivex Therapeutics (($ENLV)) announced an update on their ongoing clinical study. Enlivex Therapeutics is conducting a Phase 1/2a...

8d ago

ENLV

Enlivex Completes Key Phase II Trial Milestone for Knee Osteoarthritis Treatment

Enlivex ( ($ENLV) ) has shared an announcement. On July 28, 2025, Enlivex Therapeutics announced that all 134...

18d ago

ENLV

Enlivex Therapeutics to present clinical data of Allocetra in osteoarthritis

Enlivex Therapeutics (ENLV) announced that it will present a poster at the European Alliance of Associations for Rheumatology,...

2M ago

ENLV

Enlivex Reports Q1 2025 Financial Results with Reduced Loss

An update from Enlivex ( ($ENLV) ) is now available. Enlivex Therapeutics Ltd. released its unaudited condensed consolidated...

3M ago

ENLV

Enlivex Therapeutics selected to present at Israeli BioMed 2025 conference

Enlivex Therapeutics (ENLV) announced that the Company has been selected to present at the upcoming Israeli BioMed 2025...

3M ago

ENLV

Enlivex Therapeutics files $300M mixed securities shelf

17:12 EDT Enlivex Therapeutics (ENLV) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

4M ago

ENLV

Enlivex’s Promising Clinical Progress and Strategic Collaborations Justify Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Enlivex (ENLV – Research Report) today and set...

4M ago

ENLV

Enlivex to Present Allocetra™ Insights at OARSI 2025

Enlivex ( ($ENLV) ) has issued an update. On April 23, 2025, Enlivex Therapeutics announced its participation in...

4M ago

ENLV

Enlivex Completes Phase II Enrollment for Osteoarthritis Trial

Enlivex ( ($ENLV) ) has issued an update. On April 21, 2025, Enlivex Therapeutics announced the completion of...

4M ago

ENLV

Enlivex completed enrollment of patients in Phase II trial of Allocetra

Enlivex Therapeutics (ENLV) announced that the Company completed enrollment of all patients in the Phase II stage of...

4M ago

ENLV

Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment

Enlivex ( ($ENLV) ) has provided an announcement. On April 3, 2025, Enlivex Therapeutics announced the dosing of...

4M ago

ENLV

ENLV FAQ

What was Enlivex Therapeutics Ltd’s price range in the past 12 months?

Enlivex Therapeutics Ltd lowest stock price was $0.81 and its highest was $1.78 in the past 12 months.

What is Enlivex Therapeutics Ltd’s market cap?

Enlivex Therapeutics Ltd’s market cap is $37.44M.

When is Enlivex Therapeutics Ltd’s upcoming earnings report date?

Enlivex Therapeutics Ltd’s upcoming earnings report date is May 23, 2025 which is 84 days ago.

How were Enlivex Therapeutics Ltd’s earnings last quarter?

Enlivex Therapeutics Ltd released its earnings results on May 24, 2024. The company reported -$0.25 earnings per share for the quarter, the consensus estimate of -$0.25 by $0.

Is Enlivex Therapeutics Ltd overvalued?

According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Enlivex Therapeutics Ltd pay dividends?

Enlivex Therapeutics Ltd does not currently pay dividends.

What is Enlivex Therapeutics Ltd’s EPS estimate?

Enlivex Therapeutics Ltd’s EPS estimate is -0.15.

How many shares outstanding does Enlivex Therapeutics Ltd have?

Enlivex Therapeutics Ltd has 23,849,936 shares outstanding.

What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?

Enlivex Therapeutics Ltd reported an EPS of -$0.25 in its last earnings report, expectations of -$0.25. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?

Currently, no hedge funds are holding shares in ENLV

Enlivex Stock Smart Score

Neutral

Fundamentals

Return on Equity

-60.35%

Trailing 12-Months

Asset Growth

-22.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Enlivex Therapeutics Ltd

Enlivex (NASDAQ: ENLV) is a clinical-stage biopharmaceutical company engaged in the development of innovative immunotherapy treatments. The company is primarily focused on discovering and developing cell therapies designed to treat life-threatening conditions resulting from the overreaction of the immune system, such as sepsis and cancer. Enlivex's core product candidate is Allocetra, a cell therapy intended to modulate immune system responses and restore balance to the immune system.